VLP Therapeutics
Biotechnology company developing next-generation vaccine and immunotherapy platforms based on virus-like particle (VLP) engineering and replicon/self-amplifying RNA delivery. Focus areas include preventative and therapeutic vaccines (infectious disease and cancer), platform R&D (antigen display on VLPs, replicon gene delivery, nucleoside-modified saRNA), preclinical evaluation, and early-stage clinical development in collaboration with academic and commercial partners.
Industries
Nr. of Employees
small (1-50)
Patents
Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
US-11345726-B2
View Details
Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein
US-11345726-B2
View DetailsProducts
Malaria vaccine candidate (clinical-stage)
A VLP-based malaria vaccine candidate progressed to IND clearance and Phase I/IIa clinical recruitment to assess safety, immunogenicity and efficacy.
Tetravalent dengue VLP vaccine candidate
Tetravalent dengue virus-like particle vaccine demonstrating neutralizing antibody induction and reduced viral replication in non-human primates.
Replicon / saRNA SARS-CoV-2 vaccine candidates (preclinical/early clinical)
Self-amplifying RNA vaccine candidates with modified nucleosides and formulations evaluated for safety, immunogenicity, and optimal dosing; includes work toward lyophilized formulations for patch delivery.
Cancer immunotherapy candidate (VRP-based) — Phase 1
A virus replicon particle-based cancer immunotherapy program initiated in a Phase 1 clinical trial in collaboration with a clinical center to assess safety and immune responses.
VLPONC-01
A new cancer immunotherapy developed by VLP Therapeutics, currently in Phase 1 clinical trial in collaboration with Stanford Medicine, using VRP technology for tumor immunotherapy.
VLPCOV-02
A SARS-CoV-2 self-amplifying RNA (saRNA) vaccine with modified 5-methylcytosine base, reported for safety, immunogenicity, and optimal dosing.
Malaria vaccine candidate (clinical-stage)
A VLP-based malaria vaccine candidate progressed to IND clearance and Phase I/IIa clinical recruitment to assess safety, immunogenicity and efficacy.
Tetravalent dengue VLP vaccine candidate
Tetravalent dengue virus-like particle vaccine demonstrating neutralizing antibody induction and reduced viral replication in non-human primates.
Replicon / saRNA SARS-CoV-2 vaccine candidates (preclinical/early clinical)
Self-amplifying RNA vaccine candidates with modified nucleosides and formulations evaluated for safety, immunogenicity, and optimal dosing; includes work toward lyophilized formulations for patch delivery.
Cancer immunotherapy candidate (VRP-based) — Phase 1
A virus replicon particle-based cancer immunotherapy program initiated in a Phase 1 clinical trial in collaboration with a clinical center to assess safety and immune responses.
VLPONC-01
A new cancer immunotherapy developed by VLP Therapeutics, currently in Phase 1 clinical trial in collaboration with Stanford Medicine, using VRP technology for tumor immunotherapy.
VLPCOV-02
A SARS-CoV-2 self-amplifying RNA (saRNA) vaccine with modified 5-methylcytosine base, reported for safety, immunogenicity, and optimal dosing.
Services
Arranged contract manufacturing agreements with third-party manufacturers for vaccine formulation and production.
Research collaborations with academic institutions and clinical centers to advance preclinical and clinical programs.
Arranged contract manufacturing agreements with third-party manufacturers for vaccine formulation and production.
Research collaborations with academic institutions and clinical centers to advance preclinical and clinical programs.
Expertise Areas
- Virus-like particle vaccine development
- Replicon / self-amplifying RNA vaccine engineering
- Cancer immunotherapy (VRP-based and VLP-based approaches)
- Preclinical immunogenicity and non-human primate studies
Key Technologies
- Virus-like particles (VLPs)
- Inserted-antigen VLP antigen-display
- Replicon / self-amplifying RNA (saRNA)
- Nucleoside-modified RNA (e.g., 5-methylcytidine)
News & Updates
Initiation of a Phase 1 clinical trial in Japan for a T-cell inducing COVID-19 mRNA vaccine candidate.
Initiation of a Phase 1 clinical trial of a VRP-based cancer immunotherapy in collaboration with Stanford Medicine.
Publication reporting safety, immunogenicity, and dosing optimization for a self-amplifying RNA SARS-CoV-2 vaccine with a modified base.
Publication reporting lyophilized self-amplifying RNA vaccine formulations adapted for microneedle array patch delivery.
Two-year grant awarded to support next-generation multi-stage malaria vaccine development.
Investment award to support a Phase I clinical trial of a tetravalent dengue VLP vaccine.
Initiation of a Phase 1 clinical trial in Japan for a T-cell inducing COVID-19 mRNA vaccine candidate.
Initiation of a Phase 1 clinical trial of a VRP-based cancer immunotherapy in collaboration with Stanford Medicine.
Publication reporting safety, immunogenicity, and dosing optimization for a self-amplifying RNA SARS-CoV-2 vaccine with a modified base.
Publication reporting lyophilized self-amplifying RNA vaccine formulations adapted for microneedle array patch delivery.
Two-year grant awarded to support next-generation multi-stage malaria vaccine development.
Investment award to support a Phase I clinical trial of a tetravalent dengue VLP vaccine.